BC
IOVA icon

Brookfield Corp’s Iovance Biotherapeutics IOVA Stock Holding History

Brookfield Corp’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,888
Closed -$464K – 671
2022
Q1 		$464K Buy
27,888
+12,749
+84% +$197K ﹤0.01% 550
2021
Q4 		$289K Buy
+15,139
New +$333K ﹤0.01% 585

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Brookfield Corp's IOVA Position: Q2 2022 in Review

Brookfield Corp sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 27,888 shares — an estimated $464K sold.

Brookfield Corp first reported a position in IOVA in Q4 2021 and held it in 2 quarters. The position peaked at $464K in Q1 2022. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Brookfield Corp reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Brookfield Corp sold 27,888 Iovance Biotherapeutics shares in Q2 2022, an estimated $464K.
  • Brookfield Corp first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 2 quarters.
  • Brookfield Corp's Iovance Biotherapeutics position peaked at $464K in Q1 2022.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Brookfield Corp's 13F filing for Q2 2022, filed 15 Aug 2022.